Synopsis

Keywords: Body: Liver

Gadoxetic acid (GA) is a liver-specific MRI contrast agent that has been introduced for the diagnostic work-up of chronic diffuse liver disease and focal liver lesions combining dynamic contrast-enhanced (CE) and hepatobiliary phase imaging (HBP). For the assessment of focal liver lesions, this agent offers the possibility of distinguishing focal nodular hyperplasia (FNH) from hepatic adenoma (HA), the identification of early hepatocellular carcinoma (HCC) and the pre-operative assessment of metastasis in the liver parenchyma.The hepatic GA uptake, a reflection of liver function, correlates with chronic diffuse liver disease severity, and its use for assessing liver and biliary function is under active investigation. Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary.

Synopsis

Gadoxetic acid (GA) is a liver-specific MRI contrast agent that has been introduced for the diagnostic work-up of chronic diffuse liver disease and focal liver lesions combining dynamic contrast-enhanced (CE) and hepatobiliary phase imaging (HBP). For the assessment of focal liver lesions, this agent offers the possibility of distinguishing focal nodular hyperplasia (FNH) from hepatic adenoma (HA), the identification of early hepatocellular carcinoma (HCC) and the pre-operative assessment of metastasis in the liver parenchyma.The hepatic GA uptake, a reflection of liver function, correlates with chronic diffuse liver disease severity, and its use for assessing liver and biliary function is under active investigation. Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary.

Acknowledgements

No acknowledgement found.

References

No reference found.